Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11

JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate) Inhalation Powder for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news